Canine pododermatitis is not a single disease but a complex reactive pattern resulting from the dynamic interaction between primary causes, predisposing factors, and perpetuating elements. Though frequent in clinic, its management remains frustrating as it masks considerable etiological diversity, ranging from environmental allergy (CAD) to autoimmune disorders (pemphigus) or metabolic diseases (hepatocutaneous syndrome).

Inadequate management, often limited to empirical antibiotic therapy, inevitably leads to chronicity. This state is established through furunculosis and irreversible dermal fibrosis, promoting the emergence of multidrug-resistant strains (MRSP).

The diagnostic approach must be sequential and exhaustive (history, scrapings, cytology). Treatment, which is inherently multimodal, relies on the new ISCAID 2025 guidelines that prioritize topical therapy to combat antibiotic resistance. Innovations like Fluorescence Biomodulation (Phovia) offer new perspectives for accelerating the healing of deep forms. The key to success lies in elucidating and managing the primary cause for lasting recovery.

La pododermatite canine n'est pas une maladie unique, mais un patron réactionnel complexe issu de l'interaction dynamique entre causes primaires, facteurs prédisposants et éléments perpétuants. Bien que fréquente en clinique, sa gestion reste frustrante car elle masque une diversité étiologique considérable, allant de l'allergie environnementale (DAC) aux troubles auto-immuns (pemphigus) ou métaboliques (syndrome hépatocutané).

Une prise en charge inadéquate, souvent limitée à l'antibiothérapie empirique, mène inexorablement à la chronicité. Celle-ci s'installe via la furonculose et la fibrose dermique irréversible, favorisant l'émergence de souches multirésistantes (SPRM).

L'approche diagnostique doit être séquentielle et exhaustive (anamnèse, raclages, cytologie). Le traitement, par essence multimodal, s'appuie sur les nouvelles directives ISCAID 2025 qui privilégient la thérapie topique pour combattre l'antibiorésistance. Des innovations comme la Biomodulation par Fluorescence (Phovia) offrent de nouvelles perspectives pour accélérer la guérison des formes profondes. La clé du succès réside dans l'élucidation et la gestion de la cause primaire pour un rétablissement durable.

Pseudomonas aeruginosa is a major opportunistic pathogen in veterinary dermatology, responsible for often chronic, severe, and painful otitis and pyoderma. Its management is a constant clinical challenge due to its dual ability to form biofilms, true protective fortresses, and to develop multiple drug resistance (MDR). These strategies render conventional treatments ineffective and necessitate a rigorous, integrated therapeutic approach to hope for a lasting cure.